Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
injection
|
| gptkbp:approvedBy |
gptkb:FDA
2001 |
| gptkbp:ATCCode |
gptkb:B03XA02
|
| gptkbp:CASNumber |
gptkb:208734-13-2
|
| gptkbp:contraindication |
uncontrolled hypertension
|
| gptkbp:drugClass |
erythropoietin analog
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:darbepoetin_alfa
|
| gptkbp:halfLife |
21 hours (IV)
49 hours (SC) |
| https://www.w3.org/2000/01/rdf-schema#label |
Aranesp
|
| gptkbp:indication |
reduce need for red blood cell transfusions
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:mechanismOfAction |
erythropoiesis-stimulating agent
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
edema
hypertension cough dyspnea thromboembolic events |
| gptkbp:storage |
2–8°C
|
| gptkbp:UNII |
QXW8YN15FJ
|
| gptkbp:usedFor |
gptkb:anemia
chronic kidney disease chemotherapy-induced anemia |
| gptkbp:bfsParent |
gptkb:Amgen
|
| gptkbp:bfsLayer |
6
|